Trials / Completed
CompletedNCT00562575
Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides
A Randomised, Double-blind, Placebo Controlled Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics Profile of SLx-4090 Over 14 Days Dosing in Subjects With High Triglyceride Values
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Response Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to investigate the effect of oral doses of SLx-4090 over 14 days on subjects with high triglycerides.
Detailed description
1. Serum triglycerides 2. Serum lipids and lipoproteins 3. Safety and tolerability
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SLx-4090 | |
| DRUG | Placebo |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2007-11-22
- Last updated
- 2023-11-18
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00562575. Inclusion in this directory is not an endorsement.